About Us & Our Technology

Nectin Therapeutics is an early-stage company established in 2017 based on a collaboration of the Hebrew University of Jerusalem and the University of Rijeka, Croatia.

At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies that overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.